The strengths of this study include its novel demonstration that pre-treatment PLC is significantly associated with prognosis in patients with cervical cancer receiving ICI therapy, highlighting its potential utility for risk stratification and treatment planning in future prospective trials. This evidence concerns the gene HSPG2 and cervical carcinoma.